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Immune Response to Recombinant Escherichia coli Iss Protein in Poultry
Abstract
Colibacillosis accounts for significant losses to the poultry industry, and control efforts are hampered by
limited understanding of the mechanisms used by avian pathogenic Escherichia coli (APEC) to cause disease.
We have found that the presence of the increased serum survival gene (iss) is strongly associated with APEC
but not with commensal E. coli, makingiss, and the protein it encodes (Iss), candidate targets of colibacillosis
control procedures. To assess the potential of Iss to elicit a protective response in chickens against APEC
challenge, Iss fusion proteins were produced and administered subcutaneously to four groups of 2-wk-old
specific-pathogen-free leghorn chickens. At 4 wk postimmunization, birds were challenged with APEC from
serogroups O2 and O78 via intramuscular injection. At 2 wk postchallenge, birds were necropsied, and lesions
consistent with colibacillosis were scored. Also, sera were collected from the birds pre- and postimmunization,
and antibody titers to Iss were determined. Immunized birds produced a humoral response to Iss, and they
had significantly lower lesion scores than the unimmunized control birds following challenge with both APEC
strains. Birds that received the smallest amount of immunogen had the lowest lesion scores. Although further
study will be needed to confirm the value of Iss as an immunoprotective antigen, these preliminary data
suggest that Iss may have the potential to elicit significant protection in birds against heterologous E. coli
challenge.
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SUMMARY. Colibacillosis accounts for significant losses to the poultry industry, and control efforts are hampered by limited
understanding of the mechanisms used by avian pathogenic Escherichia coli (APEC) to cause disease. We have found that the
presence of the increased serum survival gene (iss) is strongly associated with APEC but not with commensal E. coli, making iss, and
the protein it encodes (Iss), candidate targets of colibacillosis control procedures. To assess the potential of Iss to elicit a protective
response in chickens against APEC challenge, Iss fusion proteins were produced and administered subcutaneously to four groups of
2-wk-old specific-pathogen-free leghorn chickens. At 4 wk postimmunization, birds were challenged with APEC from serogroups
O2 and O78 via intramuscular injection. At 2 wk postchallenge, birds were necropsied, and lesions consistent with colibacillosis
were scored. Also, sera were collected from the birds pre- and postimmunization, and antibody titers to Iss were determined.
Immunized birds produced a humoral response to Iss, and they had significantly lower lesion scores than the unimmunized control
birds following challenge with both APEC strains. Birds that received the smallest amount of immunogen had the lowest lesion
scores. Although further study will be needed to confirm the value of Iss as an immunoprotective antigen, these preliminary data
suggest that Iss may have the potential to elicit significant protection in birds against heterologous E. coli challenge.
RESUMEN. Nota de Investigacio´n—Repuesta inmune a la proteı´na recombinante Iss de Escherichia coli en aves dome´sticas.
La colibacilosis es responsable de pe´rdidas significativas en la industria avı´cola y los esfuerzos por controlarla se ven obstaculizados
por el desconocimiento de los mecanismos utilizados por la Escherichia coli pato´gena aviar de causar la enfermedad. Nosotros hemos
encontrado que la presencia del gen de sobrevivencia se´rica incrementada esta´ fuertemente asociado con la Escherichia coli pato´gena
aviar pero no con E. coli comensales, lo cual convierte a este gen y a la proteı´na para la cual codifica (proteı´na de sobrevivencia se´rica
incrementada) en un objetivo para los procedimientos de control de la colibacilosis. Con la finalidad de evaluar el potencial de la
proteı´na de sobrevivencia se´rica incrementada de generar una respuesta protectora contra un desafı´o con Escherichia coli pato´gena
en pollos, se generaron proteı´nas de fusio´n de la proteı´na de sobrevivencia se´rica incrementada que fueron administradas
subcuta´neamente a cuatro grupos de pollos leghorn libres de pato´genos especı´ficos de dos semanas de edad. La aves fueron
desafiadas por inyeccio´n intramuscular a las cuatro semanas de edad con Escherichia coli pato´gena de los serogrupos O2 y O78. Las
aves se sacrificaron dos semanas posteriores al desafı´o y se tomo´ registro de las lesiones consistentes con colibacilosis. Adema´s, se
tomaron muestras de suero antes y despue´s de la inmunizacio´n y se determinaron los tı´tulos de anticuerpos contra la proteı´na de
sobrevivencia se´rica incrementada. Luego del desafı´o con ambas cepas de Escherichia coli pato´genas, las aves inmunizadas generaron
una respuesta humoral contra la proteı´na de sobrevivencia se´rica incrementada y mostraron valores de lesiones menores que las aves
control no inmunizadas. Las aves que recibieron la menor cantidad de inmuno´geno tuvieron los registros de lesiones ma´s bajos.
Aunque estudios adicionales sera´n necesarios para confirmar el valor de la proteı´na de supervivencia incrementada en suero como
un agente inmunoprotector, el presente estudio sugiere que la proteı´na de sobrevivencia se´rica incrementada puede poseer el
potencial de generar proteccio´n significativa en aves contra desafı´os hetero´logos de E. coli.
Key words: APEC, avian colibacillosis, immunization, Iss
Abbreviations: APEC ¼ avian pathogenic E. coli; cAMP ¼ cyclic adenosine monophosphate; CFU ¼ colony-forming unit;
ELISA ¼ enzyme-linked immunosorbant assays; GST ¼ glutathione S-transferase; GST-Iss ¼ Iss protein fused to glutathione
S-transferase; IPTG ¼ isopropyl-beta-D-thiogalactopyranoside; LB ¼ Luria–Bertani; PBS ¼ phosphate-buffered Saline; PBSt ¼
phosphate-buffered saline with 0.05% Tween 20; SDS-PAGE ¼ sodium dodecyl sulfate–polyacrylamide gel electrophoresis
Colibacillosis, caused by avian pathogenic Escherichia coli
(APEC), is a major problem for the poultry industry in the United
States resulting in significant annual losses (2). One of the problems
in colibacillosis control is that no single bacterial trait has been
identified that can be used as an identifier of virulent avian isolates
(2) or as a target of control strategies. Previous work showed that
complement resistance may play an important role in APEC
virulence (14,19,20,28), and the increased serum survival gene or iss
(4), which is associated with E. coli complement resistance (4,6,7),
was found significantly more often in APEC than it was in the E. coli
isolates of apparently healthy birds (22,23). This strong association
between iss and APEC suggested that iss-centric strategies might be
useful in colibacillosis control.
For example, Iss, the protein encoded by iss (3,13), might be
useful as an immunogen capable of eliciting a protective response
against APEC infection in birds. If Iss could stimulate an
immunoprotective response in birds, it might have wide-ranging
benefits, because iss is found in APEC of many serogroups and in
APEC isolated from various lesion types, avian host species, and
forms of colibacillosis (22,23). This widespread distribution of iss
among APEC suggests that an Iss-based vaccine could provide broad
protection to birds against heterologous APEC challenge. Computer
analysis of Iss’ predicted amino acid sequence has suggested that
many portions of Iss are antigenic (13), and Iss is thought to be
exposed on the bacterial surface in intact E. coli (3), meaning that it
is accessible to the host’s immune system. Such observations suggestCCorresponding author.
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that Iss may have the ability to evoke an immunoprotective response
in birds against APEC that would have wide application.
Consequently, in the present study, Iss was expressed and purified,
and its potential to elicit an immunoprotective response against
heterologous APEC challenge in chickens was assessed.
MATERIALS AND METHODS
Bacterial strains and plasmids. Strains used were E. coli BL21
(DE3) (Stratagene, La Jolla, CA), E. coli APEC-C-O2, and E. coli
APEC-C-O78. Escherichia coli BL21 was used for expression of GST-Iss
and E. coli APEC-C-O2 and APEC-C-O78 were used in experimental
challenges. APEC-C-O2 is an APEC of the O2 serogroup, and APEC-
C-O78 is an APEC of the O78 serogroup. The O2 and O78 serogroups
are among the most common ones causing disease in birds (25). All
strains were maintained on Luria–Bertani (LB) agar (Difco, Detroit, MI)
with ampicillin (100 lg/ml; Amresco, Solon, OH) where appropriate.
pGEX-6P-3 (Pharmacia Biotech, Piscataway, NJ), a plasmid expression
vector designed for production of proteins fused to glutathione-S-
transferase (GST), was used in these studies. pLN330 is composed of
pGEX-6P-3 with the iss gene sequence (GenBank accession number
AF0422279) without the coding region for the signal sequence (the first
72 nucleotides of iss) (11). Using pLN330, Iss protein, fused to
glutathione S-transferase (GST-Iss), can be expressed in E. coli BL21.
Expression and solubilization of Iss fusion proteins.
Expression of GST-Iss from pLN330 was induced with isopropyl-beta-
D-thiogalactopyranoside (IPTG) as previously described (11). Induced
cells were lysed with B-PER bacterial protein extraction reagent (Pierce,
Rockford, IL) according to manufacturer’s instructions. Inclusion bodies
containing GST-Iss were solubilized with inclusion body solubilization
reagent according to manufacturer protocols (Pierce). Protein was
refolded by dialysis against decreasing concentrations of urea and finally
against Tris buffer (25 mM Tris-HCl, 150 mM NaCl, pH 7.5).
Protein purification. Purification of GST-Iss and Iss was achieved
through use of an affinity matrix. The refolded protein was combined
with a 50% slurry of glutathione sepharose 4B beads (Pharmacia) and
incubated for 1 hr at 4 C. The mixture was added to a 10-cm3 column,
and the ‘‘flow-through’’ was collected. The column was washed three
times with phosphate-buffered saline (PBS). For GST-Iss purification,
the fusion protein was eluted with glutathione elution buffer (10 mM
glutathione, 50 mM Tris, pH 8.0). For Iss purification, sepharose beads
with bound fusion protein were resuspended in PreScission cleavage
buffer (50 mM Tris-HCl, pH 7.0, 150 mM NaCl, 1 mM EDTA,
1 mM dithiothreitol) (Pharmacia). The fusion protein was cleaved
using PreScission protease (Pharmacia). The mixture was added to a 10-
cm3 column, and Iss was eluted with cleavage buffer. Purification of
the protein was assessed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) (18). Protein samples were separated on
15% acrylamide Tris-HCl gels (Bio-Rad, Hercules, CA) and stained
with Blue-Bandit protein stain (Amresco, Solon, OH).
Test animals. One hundred twenty-eight 2-wk-old specific-
pathogen-free leghorn chickens were obtained from Charles River
Laboratories (Boston, MA). All chickens were from the same hatch.
Birds were divided into eight groups of 16 as indicated in Table 1. Birds
were placed in stainless steel HEPA-filtered negative-pressure isolators
1 wk before vaccination. Birds were fed and watered ad libitum and
were handled according to Institution Animal Care and Use protocols.
Serology. Three days before vaccination and challenge, birds from
groups 1A, 2A, 3A, and 4A were bled from a wing vein to obtain serum
samples. Sera were used to perform antigen-specific enzyme-linked
immunosorbant assays (ELISA) to determine the presence of antibodies
specific for GST-Iss and purified Iss using methods previously described
(10). Briefly, coating antigen (either GST-Iss or Iss) was diluted to 2–10
lg/ml in coating buffer (0.02 M carbonate, 0.03 bicarbonate, pH 9.6).
The wells were blocked with 3% solution of bovine serum albumin,
dissolved in coating buffer. To determine antibody titers, sera were
serially diluted in phosphate-buffered saline with 0.05% Tween 20
(PBSt). Following incubation with primary antibody, the antibody was
removed and plates were washed with PBSt and incubated with goat
anti-chicken alkaline-phosphatase–conjugated IgG (Sigma, St. Louis,
MO). The plates were washed with PBSt and developed with P-
nitrophenyl phosphate. Color development was recorded at 405 nm
using an automated ELISA plate reader (model ELx808; Biotek,
Winooski, VT.).
Vaccine preparation and immunization procedure. Im-
munization protocol. Each bird was given 0.5 ml of a water-in-oil
emulsion containing either 50 lg, 10 lg, or 2 lg of GST-Iss per dose.
At 3 wk of age, each chicken in groups 1A, 1B, 2A, 2B, 3A, and 3B
received a 0.5-ml dose of the vaccine (Table 1). Birds in groups 4A and
4B were not vaccinated (nonvaccinated controls). The injections were
given subcutaneously in the back of the neck at the midpoint between
the head and body.
Challenge infection. Four weeks following vaccination, each bird
was subjected to challenge with an APEC strain. Each bird in each group
was given a 1.0-ml intramuscular injection of either 108.72 colony-
forming units (CFUs) of APEC-C-O2 or 108.89 CFUs of APEC-C-
O78, as indicated in Table 1. Birds were observed for 14 days following
challenge. Birds that died were necropsied and observed for lesions
consistent with colibacillosis; cultures of bone marrow were taken for
bacterial isolation on eosin methylene blue agar. Presumptive isolates
were verified with API 20e strips (bioMerieux, Durham, NC). After the
observation period, birds that survived were euthanatized, necropsied,
and observed for lesions consistent with colibacillosis. Lesions consistent
with colibacillosis, including mild or severe airsacculitis, perihepatitis,
pericarditis, and/or death were scored according to a system outlined
in Table 2.
Biostatistics. Efficacy of the vaccine against challenge was evaluated
by average lesion scores of vaccinates, as compared to unvaccinated
birds. Data were analyzed by the chi-square 2-by-2 test with the
significance at the P  0.05 level. For a valid test, the average lesion
score of the positive control group must have been 2.0.
RESULTS
As previously described, iss was cloned into pGEX-6P-3 to
produce a GST-Iss fusion protein (11). GST-Iss expression was
induced with IPTG; the fusion was solubilized with commercial kits,
purified by affinity chromatography, and its identity confirmed by
Table 1. Vaccine level and challenge serogroup.
Group
Number
of birds
Vaccine level
(lg/dose)
Challenge
serogroup
1A 16 50 O2
1B 16 50 O78
2A 16 10 O2
2B 16 10 O78
3A 16 2 O2
3B 16 2 O78
4A 16 0 O2
4B 16 0 O78
Table 2. Scoring system.
Score Lesions
0 No lesion
1 Cloudy air sacs (mild airsacculitis)
2 Fibrinous airsacculitis (severe airsacculitis)
3 Fibrinous airsacculitis and pericarditis
4 Fibrinous airsacculitis, pericarditis, perihepatitis, or death
(must reisolate E. coli from the bone marrow of the
femur for confirmation if dead)
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SDS-PAGE (Fig. 1). Purified Iss was obtained by cleaving Iss from
the GST fusion partner and confirmed by SDS-PAGE (Fig. 1).
Chickens immunized with GST-Iss were able to generate
a humoral immune response against GST-Iss and purified Iss as
compared to controls. Birds that received a higher dose of GST-Iss
had average antibody titers of 10,000 to 100,000 against GST-Iss,
whereas birds that received a lower dose had average titers of 1000
(Table 3). Sera from birds also recognized purified Iss. Birds that
received a high dose of fusion protein had average antibody titers of
10,000 against purified Iss, whereas birds that received lower doses
had lower average titers of 1000 (Table 3).
During the observation period following challenge, no birds died
that were challenged with APEC-C-O2. For birds challenged with
APEC-C-O78, no birds died in group 1B; four birds died in group
2B (three of which cultured positive for E. coli); one bird, which was
culture-positive for E. coli, died in group 3B; and two birds, both
of which were culture-positive for E. coli, ied in group 4B. Birds
had lower lesion scores when immunized with GST-Iss, regardless of
the challenge strain used, as compared to controls. Among the
vaccinated birds, those that received smaller doses of GST-Iss had
lower lesions scores when challenged with APEC of the O2 or O78
serogroups (Table 4).
DISCUSSION
As previously stated, avian colibacillosis is a costly disease to the
poultry industry, accounting for multimillion-dollar losses annually
(2), making efficacious colibacillosis control measures highly
desirable. Colibacillosis control frequently focuses on management
approaches designed to reduce predisposing conditions among
production birds, such as viral or mycoplasma infections (2).
However, management strategies that have controlled colibacillosis
in the past may not be as effective in the future. Also, use of
antimicrobial agents in animal production is being given close
scrutiny at this time with limitations being placed on the use of
certain therapeutic agents in poultry production (26,27). Conse-
quently, control of avian colibacillosis using vaccines in certain
situations may prove desirable.
Thus far, vaccines designed to prevent avian colibacillosis have
been met with mixed results. Vaccines against APEC of various
serogroups have been produced (1,5,8,9,12,15,16,17,21,24). Many
of these have only been effective against homologous challenge.
Kwaga et al. (17) attenuated a strain of APEC O2 serogroup by
mutating the carAB operon that encodes genes for carbamoyl-
phosphophatase synthetase, essential for arginine and pyrimidine
biosynthesis. This vaccine was effective in turkeys against a homol-
ogous APEC challenge but not a heterologous challenge. In a study
by Peighambari and colleagues (21), APEC strains of O2 and O78
serogroups were attenuated by deletion of cya and crp, which encode
39,59-cyclic adenosine monophosphate (cAMP) and cAMP receptor
protein, respectively. The cya and crp mutant of the E. coli O2
strain provided protection in chickens challenged with a homologous
strain, but again, not against heterologous challenge. This failure to
protect against heterologous challenge may prove a critical limitation
of colibacillosis vaccines because APEC are quite diverse in terms of
serogroup (23).
Targeting a surface-exposed structure found in most APEC,
regardless of serogroup, would seem to be a logical approach to the
development of a colibacillosis vaccine. It is thought that the wide-
spread distribution of iss/Iss across APEC may avoid the limitations
of some of these other vaccines. The iss gene is strongly associated
with APEC of various serogroups but not with fecal E. coli isolates
from apparently healthy birds (22,23), making iss, and the protein it
encodes, a potential marker for virulent avian E. coli. iss was cloned
into the plasmid pGEX-6P-3, and the resulting construct was used
Fig. 1. SDS-PAGE of the proteins used in this study. (A) SDS-
PAGE of GST-Iss obtained after expression of pLN330 in E. coli BL21,
followed by lysis of the cells with B-PER, solubilization of the protein
with inclusion-body solubilization reagent, and purification with
glutathione sepharose 4B. Lane S ¼ molecular size standard; lane 1 ¼
E. coli BL21 cell lysate; lane 2 ¼ E. coli BL21, containing pLN330,
following induction of expression with IPTG; and lane 3 ¼ purified
GST-Iss. (B) SDS-PAGE of purified protein (Iss) obtained after cleavage
of GST-Iss with PreScission protease. Lane S¼molecular size standard;
lane 1 ¼ E. coli BL21 cell lysate; lane 2 ¼ E. coli BL21, containing
pLN330, following induction with IPTG; and lane 3 ¼ purified Iss.
Table 3. Serum antibody titers.
Group
(dose)
Anti-GST-Iss serum
antibody titers
Anti-Iss serum
antibody titers
Average titer
preimmu-
nization
Average titer
postimmu-
nization
Average titer
preimmu-
nization
Average titer
postimmu-
nization
1A (50 lg) 102 105 102 104
2A (50 lg) 102 104 102 104
3A (2 lg) 102 103 102 103
4A (none) 102 102 02 102
Table 4. Average lesion scores.
Vaccine level
(lg/dose) Challenge
Average lesion score
O2 challenge
serogroup
O78 challenge
serogroup
2 Yes 0.38* 0.56A
10 Yes 0.75* 1.87B
50 Yes 1.31 1.63**
None Yes 2 2.88C
None No 0 0
AOne bird dead postchallenge and culture-positive for E. coli with no
macroscopic lesions.
BFour birds dead postchallenge; three culture-positive for E. coli with
severe systemic lesions; and one culture-negative with no macroscopic
lesions.
CTwo birds dead postchallenge and culture-positive for E. coli with
severe systemic lesions.
*Significantly different from nonvaccinated controls (P  0.05).
**Significantly different from nonvaccinated controls (P  0.05).
(The Mann-Whitney U-test was used to determine the statistic.)
Immune response to Iss 275
to produce a GST-Iss fusion protein. Because Iss alone is quite small,
there was concern that it might not elicit a strong immune response.
Therefore, GST was selected as a fusion partner in an effort to elicit
a stronger immune response. There was also some concern that the
majority of antibodies elicited by GST-Iss would be directed against
GST and not Iss, because GST is approximately three times the size
of Iss. However, birds immunized with GST-Iss were able to produce
antibody titers against GST-Iss and Iss that were significantly dif-
ferent from unimmunized controls. Also, Iss did stimulate an
immunoprotective response against heterologous challenge. Para-
doxically, lower doses seemed to offer better protection than did
higher doses, a result we cannot account for at this time. Much more
research will be needed to determine if use of iss/Iss based vaccines
and other control strategies are practical. Based on the results of this
study, we feel that an iss/Iss based control strategy is worthy of future
consideration and study.
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